推薦產品
化驗
99.999%
形狀
rod
自燃溫度
1400 °F
製造商／商標名
Goodfellow 827-419-90
電阻係數
2.6548 μΩ-cm
長度 × 直徑
500 mm × 5.0 mm
bp
2460 °C (lit.)
mp
660.37 °C (lit.)
密度
2.7 g/mL at 25 °C (lit.)
SMILES 字串
[Al]
InChI
1S/Al
InChI 密鑰
XAGFODPZIPBFFR-UHFFFAOYSA-N
一般說明
For updated SDS information please visit www.goodfellow.com.
法律資訊
Product of Goodfellow
儲存類別代碼
13 - Non Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Ryan J Mailloux et al.
Experimental cell research, 317(16), 2231-2238 (2011-07-27)
Aluminum (Al) is a metal toxin that has been implicated in the etiology of a number of diseases including Alzheimer's, Parkinson's, dialysis encephalopathy, and osteomalacia. Al has been shown to exert its effects by disrupting lipid membrane fluidity, perturbing iron
Todd D Terhune et al.
Journal of immunotoxicology, 10(2), 210-222 (2012-09-13)
Aluminum-containing adjuvants increase the effectiveness of vaccination, but their ability to augment immune responsiveness also carries the risk of eliciting non-target responses, especially in genetically susceptible individuals. This study reviews the relevant actions of aluminum adjuvants and sources of genetic
J R Walton
Journal of Alzheimer's disease : JAD, 29(2), 255-273 (2012-02-15)
Most humans living in industrialized societies are routinely exposed to bioavailable aluminum salts in the form of additives-in commercially-prepared foods, alum-clarified drinking water, certain pharmaceuticals, sunscreens, and other topical applications. Minute amounts of this aluminum are absorbed into the circulation.
Simone Vecchi et al.
Journal of pharmaceutical sciences, 101(1), 17-20 (2011-09-16)
Aluminum (Al) salt-based adjuvants are present in a large variety of licensed vaccines and their use is widely considered for formulations in clinical trials. Although the regulatory agencies have clearly stated the acceptable levels of Al salts in vaccines for
Maire E Percy et al.
Journal of inorganic biochemistry, 105(11), 1505-1512 (2011-11-22)
In 1991, treatment with low dose intramuscular desferrioxamine (DFO), a trivalent chelator that can remove excessive iron and/or aluminum from the body, was reported to slow the progression of Alzheimer's disease (AD) by a factor of two. Twenty years later
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務